Extramedullary infiltrates of AML are associated with CD56 expression, 11q23 abnormalities and inferior clinical outcome

Leukemia Research

Volumn 28, Issue 10, 2004, Pages 1007-1011

  Chang, Hong ^a   Brandwein, Joseph ^b   Yi, Qi Long ^b   Chun, Kathy ^b   Patterson, Bruce ^a   Brien, Bill ^a,b  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

11q23; AML; CD56; Extramedullary disease; Prognostic factors

Indexed keywords

CD19 ANTIGEN; CD34 ANTIGEN; CD56 ANTIGEN; CD7 ANTIGEN; HLA DR ANTIGEN; MEMBRANE ANTIGEN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER INVASION; CANCER SURVIVAL; CELL COUNT; CELL STRUCTURE; CENTRAL NERVOUS SYSTEM DISEASE; CHROMOSOME ABERRATION; FEMALE; FLOW CYTOMETRY; GINGIVA HYPERTROPHY; HEPATOMEGALY; HUMAN; KARYOTYPE; LEUKOCYTE; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; REMISSION; SKIN INFILTRATE; SPLENOMEGALY; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD56; CENTRAL NERVOUS SYSTEM; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 11; CYTOGENETIC ANALYSIS; FEMALE; FLOW CYTOMETRY; HUMANS; LEUKEMIA, MYELOID; LEUKEMIC INFILTRATION; LYMPHATIC DISEASES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK FACTORS; SKIN; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 3843063490     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2004.01.006     Document Type: Article

References (27)

1. Byrd J.C., Edenfield W.J., Shields D.J., Dawson N.A. Extramedullary myeloid cell tumors in acute nonlymphocytic leukemia: a clinical review. J. Clin. Oncol. 13:1995;1800-1816
2. Grier H.E., Gelber R.D., Camitta B.M., Delorey M.J., Link M.P., Price K.N., et al. Prognostic factors in childhood acute myelogenous leukemia. J. Clin. Oncol. 5:1987;1026-1032
3. Ravindranath Y., Steuber C.P., Krischner J., Civin C.I., Ducore J., Vega R., et al. High-dose cytarabine for intensification of early therapy of childhood acute myeloid leukemia: a Pediatric Oncology Group study. J. Clin. Oncol. 9:1991;572-580
4. Gehan E.A., Smith T.L., Freireich E.J., Bodey G., Rodriguez V., Speer J., et al. Prognostic factors in acute leukemia. Semin. Oncol. 3:1976;271-282
5. Woods W.G., Kobrinsky N., Buckley J., Neudorf S., Sanders J., Miller L., et al. Intensively timed induction therapy followed by autologous or allogeneic bone marrow transplantation for children with acute myeloid leukemia or myelodysplatic syndrome: A Childrens Cancer Group pilot study. J. Clin. Oncol. 11:1993;1448-1457
6. Tallman M.S., Hakimian D., Shaw J.M., Lissner G.J., Russel E.J., Variakojis D. Granulocytic sarcoma is associated with the 8;21 translocation in acute myeloid leukemia. J. Clin. Oncol. 4:1993;690-697
7. Byrd J.C., Weiss R.B., Arthur D.C., Lawrence D., Baer M.R., Davey F., et al. Extramedullary leukemia adversely affects hematologic complete remission rate and overall survival in patients with t(8;21) (q22;q22): Results from cancer and leukemia group B8461. J. Clin. Oncol. 15:1997;466-475
8. Amadori S., Testi A.M., Arico M., Comelli A., Giuliano M., Madon E., et al. Prospective comparative study of bone marrow transplantation and postremission chemotherapy for childhood acute myelogenous leukemia. J. Clin. Oncol. 11:1993;1046-1054
9. Lizuka Y., Aiso M., Oshimi K., Kanemarn M., Kawamura M., Takeuchi J., et al. Myeloblastoma formation in acute myeloid leukemia. Leuk. Res. 16:1992;665-671
10. Seymour J.F., Pierce S.A., Kantrajian H.M., Keating M.J., Estey E.H. Investigation of karyotypic, morphologic and clinical features in patients with acute myeloid leukemia blast cells expressing the neural cell adhesion molecule (CD56). Leukemia. 8:1994;823-826
11. Mitelman F, editor, ISCN: An International System for Human Cytogenetic Nomenclature. Basel: Karger S, 1995.
12. Kaplan E.L., Meier P. Non parametric estimation for incomplete observations. J. Am. Stat. Assoc. 53:1958;457-481
13. SAS Institute. Additional SAS/STAT Procedures. SAS Technical Report. Cary. NC: SAS Institute 1988, p. 179.
14. Jenkin R.D., Al-Shabanah M., Al-Nasser A., El-Solh H., Al Sudairy R., Mustafa M.M., et al. Extramedullary myeloid tumors in children: the limited value of local treatment. J. Pediatr. Hematol. Oncol. 22:2000;34-40
15. Creutzig U., Harbott J., Sperling C., Riffer J., Zimmermann M., Löffier H., et al. Clinical significance of surface antigen expression in children with acute myeloid leukemia: results of study AML-BFM-87. Blood. 86:1995;3097-3108
16. Rubnitz J.E., Raimondi S.C., Halbert A.R., Tong X., Srivastava D.K., Razzouk B.I., et al. Characteristics and outcome of t(821) positive childhood acute myeloid leukemia: a single institution's experience. Leukemia. 16:2002;2072-2077
17. Byrd J.C., Weiss R.B. Recurrent granulocytic sarcoma: an unusual variation of acute myelogenous leukemia associated with 8;21 chromosomal translocation and blast expression of the neural cell adhesion molecule. Cancer. 73:1994;2107-2112
18. Schwyzer R., Sherman G.G., Cohn R.J., Poole J.E., Willem P. Granulocytic sarcoma in children with acute myeloblastic leukemia and t(8;21). Med. Pediatr. Oncol. 31:1998;144-149
19. Rubnitz J.E., Behm F.G., Downing J.R. 11q23 rearrangements in acute leukemia. Leukemia. 10:1996;74-82
20. Broeker P.L.S., Super H.G., Thirman M.J., Pomykala H., Yonebayashi Y., Tanabe S., et al. Distribution of 11q23 breakpoints within the MLL breakpoint cluster region in de novo acute leukemia and in treatment-related acute myeloid leukemia. Correlation with scaffold attachment regions and topoisomerase II consensus binding sites. Blood. 87:1996;1912-1922
21. Cimino G., Rapanotti M.C., Elia L., Biondi A., Fizzotti M., Testi A.M., et al. ALL-1 gene rearrangements in acute myeloid leukemia: association with M4-M5 French-American-British classification subtypes and young age. Cancer Res. 55:1995;1625-1628
22. A and NKH2, expressed on subsets of large granular lymphocytes. J. Clin. Invest. 75:1985;932-943
23. Lanier L.L., Testi R., Bindl J., Phillips J.H. Identity of Leu-19 (CD56) leukocyte differentiation antigen and neural cell adhesion molecule. J. Exp. Med. 169:1989;2233-2238
24. Zocchi M.R., Vidal M., Poggi A. Involvement of CD56/N-CAM molecule in the adhesion of human solid tumor cell lines to endothelial cells. Exp. Cell Res. 204:1993;130-135
25. Wong K.F., Chan J.K.C., Ng C.S., Tsang W.Y.W. CD56 (NKH1)-positive hematolymphoid malignancies: an aggressive neoplasm featuring frequent cutaneous/mucosal involvement, cytoplasmic azurophilic granules, and angiocentricity. Hum. Pathol. 23:1992;798-804
26. Kern W.F., Spier C.M., Hanneman E.H., Miller T.P., Matzner M., Grogan T.M. Neural cell adhesion molecule-positive peripheral T-cell lymphoma: a rare variant with a propensity for unusual sites of involvement. Blood. 79:1992;2432-2437
27. Baer M.R., Stewart C.C., Lawrence D., Arthur D.C., Byrd J.C., Davey F.R., et al. Expression of the neural cell adhesion molecular CD56 is associated with short remission duration and survival in acute myeloid leukemia with t(8;21)(q22;q22). Blood. 90:1997;1643-1648